bpc 157 benefits for women BPC-157 Peptide Therapy: What the Research Says What Is BPC-157? The Body

Separately, RegeneRx's ophthalmic formulation RGN-259 completed Phase 3 trials (ARISE-1 and ARISE-2) for dry eye with mixed results

The 0.9% concentration is calibrated to provide effective bacteriostasis at the anticipated microbial challenge levels associated with multi-use vial access in laboratory research environments while remaining below the concentration ranges associated with peptide and protein stability perturbation in reconstituted research compound solutions

These numbers come from rodent studies scaled to a human size, not from human clinical trials

this is cell and animal evidence, not a supervised human therapy, and individual outcomes are unknown because controlled human muscle-growth studies do not exist